ReCor Medical, Inc.

FRANKFURT, Germany and PALO ALTO, Calif., May 15, 2026 /PRNewswire/ -- In recognition of World Hypertension Day 2026 on May 17th, Recor Medical, Inc. ("Recor"), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., joins the global community in raising awareness of high blood pressure and celebrating the progress being made in its detection, management, and treatment. Affecting more than one billion people worldwide, hypertension remains a leading risk factor for serious cardiovascular conditions, making continued innovation and patient engagement essential. This year's global theme, "Controlling Hypertension Together" emphasizes the importance of early detection and sustained management to support longer, healthier lives. Continue Reading Photo Recor Medical According the World Health Organization, the number of adults with hypertension doubled between 1990 and 2019 from 650 million to 1.3 billion. When left uncontrolled, hypertension can lead to serious health risks, including heart attack, stroke and kidney disease, leading to its nickname: the "silent killer". About one third of the patients who are treated for hypertension remain uncontrolled despite making healthy lifestyle changes and taking more than three medications. For these individuals, new treatment approaches are essential. One such innovation is ultrasound renal denervation (uRDN), a minimally invasive, device-based therapy designed to reduce overactive sympathetic nerve activity that contributes to high blood pressure. The Paradise™ uRDN system, developed by Recor Medical, delivers ultrasound energy to calm the overactive nerves surrounding the renal arteries, offering an additional treatment option for appropriate patients. "World Hypertension Day is a powerful reminder that we must do more to close the gap between diagnosis and control," said Helen Reeve-Stoffer, Chief Operating Officer of Recor Medical. "At Recor, we are committed to advancing innovative solutions that go beyond traditional therapies, helping physicians better manage patients whose blood pressure remains uncontrolled despite lifestyle changes and medication. We are working actively to expand access to hypertension treatments that can meaningfully improve patient outcomes and save lives." "Hypertension is arguably the most significant modifiable risk factor in medicine, yet it remains underdiagnosed and undertreated worldwide," said Dr. Shon Chakrabarti, Chief Medical Officer of Recor Medical. "We are entering a new era in hypertension care—one where device-based therapies like the Paradise procedure can reduce blood pressure alongside medications and lifestyle changes. By expanding the treatment toolbox, we can help more patients achieve meaningful and sustained blood pressure reductions." About the Paradise uRDN System The Paradise uRDN system is a novel ultrasound-based RDN technology designed to lower blood pressure by denervating the sympathetic nerves surrounding the renal arteries, reducing the overactivity that can lead to hypertension. The Paradise uRDN system delivers two to three doses of 360-degree ultrasound energy — lasting seven seconds each — through the main renal arteries to the surrounding nerves. The Paradise catheter features the exclusive HydroCooling™ system, which circulates sterile water through the balloon catheter during the procedure to help protect the renal artery wall. The Paradise uRDN system is currently commercially available for patients in the U.S. having received FDA approval in November 2023. The Paradise Ultrasound Renal Denervation system (Paradise system) is indicated to reduce blood pressure as an adjunctive treatment in hypertension patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure. Potential procedure-related adverse events including pain, vascular access site complications, and vasospasm are most common. Individual results may vary. About Recor Medical, Inc. Recor Medical, Inc., a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd. headquartered in Palo Alto, Calif., is a medical technology company dedicated to transforming the management of treatment resistant hypertension through the Paradise™ Ultrasound Renal Denervation (uRDN). The Paradise uRDN system is FDA approved for sale in the United States, CE marked and approved in markets where the CE mark is accepted, and received regulatory approval in Japan, per approved indications for use. Clinical evidence for the Paradise uRDN system includes positive outcomes in three independent, randomized, sham-controlled studies in patients with mild-to-moderate and resistant hypertension. In addition, Recor is advancing real-world evidence generation through the Global Paradise System ("GPS") Registry in the European Union and the UK, as well as the US GPS post-approval study in the United States. About Otsuka Medical Devices Co., Ltd. Otsuka Medical Devices Co., Ltd. engages in the global development and commercialization of medical devices that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical or other conventional treatment. Otsuka Medical Devices is a subsidiary of Otsuka Holdings Co., Ltd. (), a global healthcare company listed on the Tokyo Stock Exchange (JP 4578). Photo - Logo - 21% more press release views with Request a Demo

FRANKFURT, Germany and PALO ALTO, Calif., May 15, 2026 /PRNewswire/ -- In recognition of World Hypertension Day 2026 on May 17th, Recor Medical, Inc. ("Recor"), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., joins the global community in raising awareness of high blood pressure and celebrating the progress being made in its detection, management, and treatment. Affecting more than one billion people worldwide, hypertension remains a leading risk factor for serious cardiovascular conditions, making continued innovation and patient engagement essential. This year's global theme, "Controlling Hypertension Together" emphasizes the importance of early detection and sustained management to support longer, healthier lives. Continue Reading Photo Recor Medical (PRNewsfoto/Recor Medical Inc.) According the World Health Organization, the number of adults with hypertension doubled between 1990 and 2019 from 650 million to 1.3 billion. When left uncontrolled, hypertension can lead to serious health risks, including heart attack, stroke and kidney disease, leading to its nickname: the "silent killer". About one third of the patients who are treated for hypertension remain uncontrolled despite making healthy lifestyle changes and taking more than three medications. For these individuals, new treatment approaches are essential. One such innovation is ultrasound renal denervation (uRDN), a minimally invasive, device-based therapy designed to reduce overactive sympathetic nerve activity that contributes to high blood pressure. The Paradise™ uRDN system, developed by Recor Medical, delivers ultrasound energy to calm the overactive nerves surrounding the renal arteries, offering an additional treatment option for appropriate patients. "World Hypertension Day is a powerful reminder that we must do more to close the gap between diagnosis and control," said Helen Reeve-Stoffer, Chief Operating Officer of Recor Medical. "At Recor, we are committed to advancing innovative solutions that go beyond traditional therapies, helping physicians better manage patients whose blood pressure remains uncontrolled despite lifestyle changes and medication. We are working actively to expand access to hypertension treatments that can meaningfully improve patient outcomes and save lives." "Hypertension is arguably the most significant modifiable risk factor in medicine, yet it remains underdiagnosed and undertreated worldwide," said Dr. Shon Chakrabarti, Chief Medical Officer of Recor Medical. "We are entering a new era in hypertension care—one where device-based therapies like the Paradise procedure can reduce blood pressure alongside medications and lifestyle changes. By expanding the treatment toolbox, we can help more patients achieve meaningful and sustained blood pressure reductions." About the Paradise uRDN System The Paradise uRDN system is a novel ultrasound-based RDN technology designed to lower blood pressure by denervating the sympathetic nerves surrounding the renal arteries, reducing the overactivity that can lead to hypertension. The Paradise uRDN system delivers two to three doses of 360-degree ultrasound energy — lasting seven seconds each — through the main renal arteries to the surrounding nerves. The Paradise catheter features the exclusive HydroCooling™ system, which circulates sterile water through the balloon catheter during the procedure to help protect the renal artery wall. The Paradise uRDN system is currently commercially available for patients in the U.S. having received FDA approval in November 2023. The Paradise Ultrasound Renal Denervation system (Paradise system) is indicated to reduce blood pressure as an adjunctive treatment in hypertension patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure. Potential procedure-related adverse events including pain, vascular access site complications, and vasospasm are most common. Individual results may vary. About Recor Medical, Inc. Recor Medical, Inc., a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd. headquartered in Palo Alto, Calif., is a medical technology company dedicated to transforming the management of treatment resistant hypertension through the Paradise™ Ultrasound Renal Denervation (uRDN). The Paradise uRDN system is FDA approved for sale in the United States, CE marked and approved in markets where the CE mark is accepted, and received regulatory approval in Japan, per approved indications for use. Clinical evidence for the Paradise uRDN system includes positive outcomes in three independent, randomized, sham-controlled studies in patients with mild-to-moderate and resistant hypertension. In addition, Recor is advancing real-world evidence generation through the Global Paradise System ("GPS") Registry in the European Union and the UK, as well as the US GPS post-approval study in the United States. About Otsuka Medical Devices Co., Ltd. Otsuka Medical Devices Co., Ltd. engages in the global development and commercialization of medical devices that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical or other conventional treatment. Otsuka Medical Devices is a subsidiary of Otsuka Holdings Co., Ltd. (), a global healthcare company listed on the Tokyo Stock Exchange (JP 4578). Photo - Logo - SOURCE Recor Medical Inc. 21% more press release views with Request a Demo

In November 2023, Medtronic “won the big one” in renal denervation (RDN) when FDA finally approved its Symplicity Spyral RDN System — schooling us all on the power of persistence . Fast forward to 2026, and the space is rapidly evolving with new entrants. But one company is setting itself apart from the crowd by adopting the old real estate mantra of “location, location, location.” Specifically, Verve Medical is paving the way for renal pelvic denervation (RPD) technology. The Phoenix, AZ-based company recently treated the first patient in its randomized, double-blinded U.S. pilot clinical trial for uncontrolled hypertension. This milestone accelerates the company’s mission to commercialize a novel, targeted, minimally invasive therapy to address the global burden of high blood pressure. The pilot trial builds on strong results from Verve’s TUSK feasibility trial, which demonstrated an average reduction of 20 mmHg in 24-hour systolic ambulatory blood pressure among treated patients through one year of follow-up. These findings highlighted the potential of renal pelvic denervation to meaningfully reduce blood pressure in patients whose hypertension remains uncontrolled despite taking multiple medications. The renal pelvic denervation procedure takes advantage of the relationship between urology and nephrology specialties, combining urologists’ expertise in accessing the renal collecting system with nephrologists’ deep understanding of blood pressure regulation and its relationship with renal function. The RPD pilot trial is enrolling 60 patients across 10 U.S. clinical sites, with participants randomized to receive either renal pelvic denervation or a sham procedure. The first procedure was performed by Michael Borofsky, MD, associate professor and director of endourology fellowship at the University of Minnesota and M Health Fairview, who specializes in kidney stone disease and advanced endourological procedures. Renal pelvic denervation vs. arterial renal denervation Graphic courtesy of Verve Medical Verve’s renal pelvic denervation therapy directly targets overactive renal nerves — key drivers of high blood pressure — using radiofrequency energy delivered into the densely innervated renal pelvis through an outpatient procedure. Unlike traditional catheter-based renal denervation approaches that access the renal arteries from within the bloodstream, Verve’s technology leverages the patient’s natural urinary tract, which is used frequently by urologists, creating the potential for procedures to be performed in ambulatory care settings. “Hypertension remains one of the most pervasive and dangerous global health challenges, contributing to heart attacks, strokes, heart failure, kidney disease, and vascular damage,” said David Perry, CEO of Verve Medical. “For patients whose conditions remain uncontrolled despite medication, Verve’s RPD technology offers a targeted, energy‑based approach with the potential to transform care.” Location, location, location — the renal pelvic denervation difference “Cardiologists and interventional radiologists have a common pathway to treat things within the coronary arteries to the kidneys to even peripheral vascular disease, and so all of this started really with cardiology,” Perry told MD+DI . “But if you really study the nerves, they all originate in the renal pelvis.” So, Perry said Verve thinks it’s in the right location and companies using traditional catheter-based renal denervation procedures are not. “All of those nerve fibers are very superficial in the renal pelvis, and they are operating on a cellular level to determine how well the kidney is functioning to process fluids and filter fluid out of the body,” Perry said. “And so, for us, it's a really easy pathway to get to, whereas the other guys, they have devices that sometimes are so big that it limits their access to those renal branches to be able to do an ablation.” With an average reduction of 20 mmHg in 24-hour systolic ambulatory blood pressure, as shown in Verve’s feasibility trial, patients could potentially get off two medications, Perry said. “That's really significant because the drugs are just, it's not a great life. You've got pelvic pain, you're cloudy, foggy, dizzy, you're tired all the time. If you're a man, it causes [erectile dysfunction]; it's just not great,” Perry said. In other words, hypertension medication adherence is a tough hill to climb due to all the side effects from the drugs. “And so, we think location, location, location is the key to our success and the fact that it's a natural orifice, the urinary tract, that urologists can get to very easily.” And that, he said, leads to an outpatient procedure that's 20 minutes to 30 minutes in length versus an overnight stay, an hour-long procedure with other companies in the renal denervation space.